Physician profile
Ashley E Swartz
NPI 1255939237
$4,267.10
in general payments reported to CMS, 2019-2025
21 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $753 · 2022: $1,492 · 2023: $476 · 2024: $226 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220 · Travel and Lodging: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.41 |
| Travel and Lodging | $801.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,218.83 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $907.51 | 2021-2023 | Synchromedii |
| Nevro Corp. | $699.83 | 2021-2023 | Senza |
| Mml US, INC. | $269.75 | 2023-2025 | Reactiv8 |
| Abbvie INC. | $213.48 | 2022-2024 | |
| Amgen INC. | $182.23 | 2021-2022 | |
| Spr Therapeutics, INC | $164.10 | 2023-2024 | Sprint Pns System |
| Si-Bone, INC. | $132.64 | 2022 | |
| Lundbeck LLC | $111.71 | 2022 | |
| Collegium Pharmaceutical, INC. | $104.77 | 2022-2023 | Belbuca, Xtampza |
| Tactile Systems Technology INC | $43.63 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $32.69 | 2021 | |
| Merz Pharmaceuticals, LLC | $30.42 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.38 | 2022 | |
| Globus Medical, INC. | $24.28 | 2025 | Senza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $19.57 | 2021 | |
| Piramal Critical Care | $17.71 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.79 | 2023 | Horizant |
| Arbor Pharmaceuticals, INC. | $16.72 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.58 | 2023 | Austedo |
| Ipsen Biopharmaceuticals, INC | $14.48 | 2025 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Swartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.